Proactive Investors - Run By Investors For Investors

THC Global directors and CEO to participate in SPP

Shares in the company are trading at 52.5 cents, a premium to the 50-cent offer price.
three empty board seats
Crystal Mountain recently grew revenue to $991,000, a 22% increase on the previous quarter

THC Global Group Ltd (ASX:THC) has revealed that its directors and CEO have confirmed they will participate in the share purchase plan (SPP) that is underway.

Under the SPP, eligible shareholders can subscribe for up to $15,000 worth of shares priced at 50 cents.

The SPP offer is expected to close on Friday, 26 April 2019 after it opened 9 April 2019.

READ: THC Global's Canadian division boosts revenue 22% in March quarter

In a letter to shareholders on 9 April, THC’s chairman Steven Xu said: “The funds raised from the Share Purchase Plan will be applied to progress the company’s Australian medicinal cannabis activities as it transitions into full-scale production as final licences and permits are received in the near term, as well as general working capital.”

The company also released its April 2019 briefing note earlier this month, which it distributed to shareholders yesterday.

The briefing note highlighted the near term outlook for the company which included the receipt of final Australian cannabis licenses and permits enabling two manufacturing facilities and cultivation sites.

At its manufacturing facility, it is working towards first validation production, which aims to lead to high-value profitable production of up to 120,000 kilograms of oil at full capacity.

Furthermore, in the April briefing note, THC listed signing key offtake agreements for products and securing cannabis supply through domestic production in its near term outlook.

View full THC profile View Profile

THC Global Group Ltd Timeline

Related Articles

A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
rasuvo
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
woman's face
Tue
Here we take a closer look at SkinBioTherapeutics, the life sciences group that is using bacteria to improve people’s skin
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use